Study to Evaluate an Influenza Vaccine Candidate

Summary

In order to find the formulation leading to a maximal increase of the immune response while maintaining an acceptable safety profile, this study is designed to evaluate the immunogenicity, safety and reactogenicity of the different formulations of GSK Biologicals' influenza vaccine administered in adults aged 18-64 years.

Timeline

Start

2007-10-05

Primary completion

2008-05-08

Completion

2008-05-08

Drugs

Indications